• Prestige Consumer Healthcare posted fiscal 2027 Q1 net income of USD 29.2 million, down from USD 47.5 million a year earlier; diluted EPS fell to USD 0.61.
• Revenue rose 6.5% year over year to USD 265.7 million, helped by gastrointestinal and dermatological strength; Breathe Right added USD 5.9 million.
• GAAP operating income slid to USD 52.5 million from USD 71.8 million; interest expense, net climbed to USD 13.9 million from USD 10.2 million.
• Adjusted diluted EPS increased to USD 0.98 from USD 0.95, reflecting non-GAAP add-backs tied mainly to acquisition-related costs.
• Raised fiscal 2027 outlook to include acquisitions, targeting revenue of USD 1.29 billion to USD 1.32 billion; adjusted diluted EPS seen at USD 4.55 to USD 4.65.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prestige Consumer Healthcare Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.